Sydney, Australia – 9 December, 2024 | NEXSEN Biotech Pty Ltd (“NEXSEN”), a pioneering diagnostics company, is excited to announce the launch of its pre-IPO fundraising round, targeting $2 million to $3 million. With a mission to improve global health outcomes, NEXSEN is set to deliver cutting-edge point-of-care diagnostic solutions that address critical unmet medical needs.
At the heart of NEXSEN's innovation is StrepSure®, the world's first rapid diagnostic test for Group B Streptococcus (“GBS”). This revolutionary technology leverages advanced nanoparticle engineering and aptamer discovery, ensuring quick, accurate, and cost-effective diagnosis at the point of care. StrepSure® is poised to make life-saving diagnostics accessible, particularly in underserved regions, by eliminating the reliance on traditional laboratory testing.
Building on its success, NEXSEN is also developing diagnostic pipelines, including a veterinary version of StrepSure® and at-home tests for kidney function and prostate cancer screening. These advancements align with its strategy to broaden the impact of diagnostics across human and animal health.
Investment Highlights
-
High-Growth Market Potential: The global point-of-care diagnostics market is projected to reach $119.4 billion by 2029, driven by the growing need for rapid disease detection.
-
Proven Technology: With patented biomarkers and exclusive IP rights, NEXSEN is at the forefront of nano-biotech innovation.
-
Strategic Collaborations: Partnerships with RMIT University, Northern Health, and leading industry designers bolster NEXSEN’s research, development, and clinical trials.
-
Regulatory Pathway: StrepSure® is on track for FDA and TGA approval, supported by ongoing clinical trials at Northern Health in Melbourne.
-
Social Impact: Offering affordable diagnostics for low-resource settings and high-risk groups globally.
The pre-IPO funds will be used to advance market development, regulatory compliance, and the early-stage development of new diagnostic tests. This strategic move positions NEXSEN for its anticipated public listing on the ASX in April 2025.
"The pre-IPO round presents a rare opportunity for investors to support a high-impact biotech company at a pivotal moment in its growth," said Managing Director Thomas Hanly. "With our innovative technology, strategic partnerships, and commitment to saving lives, NEXSEN is primed to disrupt the diagnostic industry and deliver exceptional value to stakeholders."
Next Steps
Investors are invited to participate in this transformative journey. The pre-IPO offering will remain open until Q1 2025, with funds allocated towards global market entry strategies and finalizing regulatory approvals for StrepSure®.
For more information about NEXSEN’s pre-IPO investment opportunity, visit nexsen.bio or contact the investor relations team.
About us:
About NEXSEN Biotech
NEXSEN Biotech Pty Ltd is an Australian diagnostic company focused on building a point of care testing platform utilizing proprietary biomarker discovery, bioconjugation chemistry and nanoparticle engineering, to deliver material improvements in testing outcomes. The core of this innovation is the discovery and application of aptamers, a synthetic DNA molecule that binds selectively to identified particles with extreme sensitivity, ensuring the test only test for the target, mitigating the risk of false positives. The company has multiple products in development, including StrepSure® for early detection of Group B Streptococcus (GBS) in pregnant women and infants, VetStrep® for detection of Bovine Mastitis and at home Creatinine and Prostate Specific Antigen tests (PSA).
Contact details:
Media Contact:
Jane Morgan
JMM
jm@janemorganmanagement.com.au
